×
News Home

Do Analysts Expect ATAI Life Sciences NV (ATAI) Stock to Rise After It Is Down -13.05% in a Month?

Friday, January 14, 2022 03:34 PM | InvestorsObserver Analysts
Do Analysts Expect ATAI Life Sciences NV (ATAI) Stock to Rise After It Is Down -13.05% in a Month?

Analysts who follow ATAI Life Sciences NV (ATAI) on average expect it to gain 435.87% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns ATAI an Analyst Ranking of 69, which means it ranks higher than 69 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.8
Wall Street analysts are rating ATAI a Strong Buy today. Find out what this means to you and get the rest of the rankings on ATAI!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With ATAI Life Sciences NV Stock Today?

ATAI Life Sciences NV (ATAI) stock is trading at $5.93 as of 3:34 PM on Friday, Jan 14, a loss of -$0.29, or -4.66% from the previous closing price of $6.22. The stock has traded between $5.76 and $6.17 so far today. Volume today is light. So far 797,115 shares have traded compared to average volume of 1,307,906 shares. Click Here to get the full Stock Report for ATAI Life Sciences NV stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App